Cell & Gene Therapy​
News
What do your key players need from IT systems in your CGT processes?
Manufacturing cell and gene therapies (CGTs) usually involve the coordinated efforts of staff in treatment centres, ship...
Orchestrating the supply of different cell and gene therapies
Cell and gene therapies (CGTs) and their patient-specific delivery of therapeutics are often seen as the future of medic...
Addressing the challenges of using RNA as a therapeutic or a gene-editing tool
RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality due to their essential biologic...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Bridging the worlds of IT and CGT through analogies
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
A simplified way to register complex and innovative raw materials in Europe
The regulatory environment for registering innovative and complex raw materials differs by region and country. All natio...
Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.
The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few...
RNA: new CGT workstream to focus on this industry priority
When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they want...
Assessing EHS risks in CGT: a real-world example
In 2020, the Cell and Gene Therapy Phorum published an article Environmental Health and Biosafety Risk Assessment Guidan...
Illuminating the challenges of validating cell and gene therapies
The validation processes for general biologics and small molecule drugs are well established and there are many guidelin...
Release specifications for master cell banks – your chance to make a difference
Gene therapy (GT) is a rapidly expanding field that could potentially revolutionize curative treatments and is an exciti...
What do your key players need from IT systems in your CGT processes?
Manufacturing cell and gene therapies (CGTs) usually involve the coordinated efforts of staff in treatment centres, shipping partners, and more than one manufacturing facility. It has become complex because each new therapy seems to define a contrasting way of doing things and has a different way of...
Orchestrating the supply of different cell and gene therapies
Cell and gene therapies (CGTs) and their patient-specific delivery of therapeutics are often seen as the future of medic...
Addressing the challenges of using RNA as a therapeutic or a gene-editing tool
RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality due to their essential biologic...
Using a closure analysis method to reduce CGT contamination risks
Many cell therapy manufacturing processes use open unit manipulations. As a result, they are at risk of potential contam...
Bridging the worlds of IT and CGT through analogies
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases...
BioPhorum’s Deliverables Report 2021 – all of our content at your fingertips
Where can you read about industry trends, progress against shared challenges, and best practice solutions...
A simplified way to register complex and innovative raw materials in Europe
The regulatory environment for registering innovative and complex raw materials differs by region and country. All natio...
Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.
The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few...
RNA: new CGT workstream to focus on this industry priority
When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they want...
Assessing EHS risks in CGT: a real-world example
In 2020, the Cell and Gene Therapy Phorum published an article Environmental Health and Biosafety Risk Assessment Guidan...
Illuminating the challenges of validating cell and gene therapies
The validation processes for general biologics and small molecule drugs are well established and there are many guidelin...
Release specifications for master cell banks – your chance to make a difference
Gene therapy (GT) is a rapidly expanding field that could potentially revolutionize curative treatments and is an exciti...
BioPhorum launch new sustainability phorum
BioPhorum members have given us a clear message; to be an industry that supports sustainability is extremely important t...